CL2020003443A1 - Composiciones farmacéuticas que comprenden meloxicam - Google Patents
Composiciones farmacéuticas que comprenden meloxicamInfo
- Publication number
- CL2020003443A1 CL2020003443A1 CL2020003443A CL2020003443A CL2020003443A1 CL 2020003443 A1 CL2020003443 A1 CL 2020003443A1 CL 2020003443 A CL2020003443 A CL 2020003443A CL 2020003443 A CL2020003443 A CL 2020003443A CL 2020003443 A1 CL2020003443 A1 CL 2020003443A1
- Authority
- CL
- Chile
- Prior art keywords
- meloxicam
- pharmaceutical compositions
- drug
- compositions
- triptan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
En la presente descripción se describen composiciones que comprenden un fármaco tal como un triptano (por ejemplo, rizatriptán) y/o un AINE (por ejemplo, meloxicam) en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden administrarse por vía oral, por ejemplo, para mejorar la biodisponibilidad, la solubilidad o la farmacocinética del fármaco para el tratamiento de afecciones tales como el dolor.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693871P | 2018-07-03 | 2018-07-03 | |
| US201962802198P | 2019-02-06 | 2019-02-06 | |
| US201962803756P | 2019-02-11 | 2019-02-11 | |
| US201962835613P | 2019-04-18 | 2019-04-18 | |
| US201962846311P | 2019-05-10 | 2019-05-10 | |
| US201962860705P | 2019-06-12 | 2019-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003443A1 true CL2020003443A1 (es) | 2021-05-07 |
Family
ID=69059998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003443A CL2020003443A1 (es) | 2018-07-03 | 2020-12-30 | Composiciones farmacéuticas que comprenden meloxicam |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220096490A1 (es) |
| EP (1) | EP3817722A4 (es) |
| JP (4) | JP7237375B2 (es) |
| KR (2) | KR102815027B1 (es) |
| CN (1) | CN112384198A (es) |
| AU (3) | AU2019297360B2 (es) |
| BR (1) | BR112020026965A2 (es) |
| CA (2) | CA3105476A1 (es) |
| CL (1) | CL2020003443A1 (es) |
| CO (1) | CO2021000789A2 (es) |
| CR (1) | CR20210061A (es) |
| IL (1) | IL279442A (es) |
| MX (2) | MX2020014128A (es) |
| MY (1) | MY199007A (es) |
| NI (1) | NI202000105A (es) |
| PE (1) | PE20210401A1 (es) |
| SG (1) | SG11202012376PA (es) |
| WO (1) | WO2020010196A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602563B2 (en) | 2015-02-10 | 2023-03-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11045549B2 (en) | 2015-02-10 | 2021-06-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12485176B2 (en) | 2015-02-10 | 2025-12-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11607456B2 (en) | 2015-02-10 | 2023-03-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10933136B2 (en) | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11738085B2 (en) | 2015-02-10 | 2023-08-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617755B2 (en) | 2017-01-04 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11806354B2 (en) | 2017-01-04 | 2023-11-07 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11471465B2 (en) | 2017-01-04 | 2022-10-18 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11433079B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11801250B2 (en) | 2017-01-04 | 2023-10-31 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11433078B2 (en) | 2017-01-04 | 2022-09-06 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617756B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11865117B2 (en) | 2017-06-29 | 2024-01-09 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
| US11759522B2 (en) | 2017-06-29 | 2023-09-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11510927B2 (en) | 2017-06-29 | 2022-11-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12691123B2 (en) | 2017-06-29 | 2026-07-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10918722B2 (en) | 2017-06-29 | 2021-02-16 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617791B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11185550B2 (en) | 2017-06-29 | 2021-11-30 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| CA3179681A1 (en) * | 2020-04-06 | 2021-10-14 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US20240058354A1 (en) | 2020-04-06 | 2024-02-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12128052B2 (en) | 2020-05-28 | 2024-10-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| KR20230125826A (ko) | 2020-12-31 | 2023-08-29 | 액섬 테라퓨틱스, 인크. | 멜록시캄을 포함하는 약학 조성물 |
| US12370196B2 (en) | 2020-12-31 | 2025-07-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12005118B2 (en) | 2022-05-19 | 2024-06-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12544383B1 (en) | 2025-01-30 | 2026-02-10 | Axsome Therapeutics, Inc. | Methods of treating migraines with a combination of a meloxicam and a rizatriptan |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2234324T3 (es) * | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
| US20040214861A1 (en) * | 2003-03-28 | 2004-10-28 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine |
| WO2004089365A1 (en) * | 2003-04-11 | 2004-10-21 | Pfizer Limited | Pharmaceutical combination comprising eletriptan and sodium bicarbonate |
| BRPI0410807A (pt) * | 2003-06-06 | 2006-06-27 | Glaxo Group Ltd | composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica |
| EP3216445A1 (en) * | 2004-05-28 | 2017-09-13 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| WO2008049116A2 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| US20090068262A1 (en) * | 2007-04-04 | 2009-03-12 | Ilan Zalit | Rapid dissolution of combination products |
| US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
| CN101984960B (zh) * | 2010-10-29 | 2011-10-26 | 四川梓橦宫药业有限公司 | 苯甲酸利扎曲普坦胶囊及其制备方法 |
| SG10202010157VA (en) * | 2015-02-10 | 2020-11-27 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
| US10058614B2 (en) * | 2015-02-10 | 2018-08-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10471014B2 (en) * | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
-
2019
- 2019-07-03 CR CR20210061A patent/CR20210061A/es unknown
- 2019-07-03 MX MX2020014128A patent/MX2020014128A/es unknown
- 2019-07-03 WO PCT/US2019/040495 patent/WO2020010196A1/en not_active Ceased
- 2019-07-03 MY MYPI2020007158A patent/MY199007A/en unknown
- 2019-07-03 SG SG11202012376PA patent/SG11202012376PA/en unknown
- 2019-07-03 KR KR1020217001263A patent/KR102815027B1/ko active Active
- 2019-07-03 JP JP2020573124A patent/JP7237375B2/ja active Active
- 2019-07-03 CN CN201980044810.8A patent/CN112384198A/zh active Pending
- 2019-07-03 CA CA3105476A patent/CA3105476A1/en active Pending
- 2019-07-03 KR KR1020257017422A patent/KR20250085839A/ko active Pending
- 2019-07-03 PE PE2020002265A patent/PE20210401A1/es unknown
- 2019-07-03 BR BR112020026965-4A patent/BR112020026965A2/pt unknown
- 2019-07-03 EP EP19830839.7A patent/EP3817722A4/en active Pending
- 2019-07-03 AU AU2019297360A patent/AU2019297360B2/en active Active
- 2019-07-03 CA CA3316259A patent/CA3316259A1/en active Pending
-
2020
- 2020-12-14 IL IL279442A patent/IL279442A/en unknown
- 2020-12-17 MX MX2024005716A patent/MX2024005716A/es unknown
- 2020-12-29 NI NI202000105A patent/NI202000105A/es unknown
- 2020-12-30 CL CL2020003443A patent/CL2020003443A1/es unknown
-
2021
- 2021-01-25 CO CONC2021/0000789A patent/CO2021000789A2/es unknown
- 2021-12-10 US US17/547,676 patent/US20220096490A1/en not_active Abandoned
-
2022
- 2022-10-17 AU AU2022252856A patent/AU2022252856B2/en active Active
-
2023
- 2023-02-21 JP JP2023024882A patent/JP7485807B2/ja active Active
-
2024
- 2024-05-02 JP JP2024074670A patent/JP7815319B2/ja active Active
-
2025
- 2025-03-20 AU AU2025202015A patent/AU2025202015A1/en active Pending
- 2025-11-28 JP JP2025207561A patent/JP2026020365A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021000789A2 (es) | Composiciones farmacéuticas que comprenden meloxicam | |
| CO2019008364A2 (es) | Composiciones farmacéuticas que comprenden meloxicam | |
| MX2017010304A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| EP4467600A3 (en) | Pharmaceutical compositions comprising meloxicam | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2017016862A (es) | Composicion farmaceutica estable para administracion oral. | |
| DOP2010000327A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona | |
| ECSP21006974A (es) | Composiciones farmacéuticas que comprenden meloxicam | |
| AR072795A1 (es) | Una formulacion de fenofibrato, una capsula para administracion oral que comprende dicha formulacion y un proceso para la fabricacion de dicha formulacion | |
| ECSP15033649A (es) | Un medicamento combinado que comprende fenilefrina y paracetamol | |
| MY203481A (en) | Pharmaceutical compositions comprising meloxicam | |
| CL2019002446A1 (es) | Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas. | |
| TN2016000561A1 (en) | Stabilized desmopressin | |
| AR099330A1 (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
| UY35324A (es) | Composiciones farmacéuticas que contienen dexketoprofeno y tramadol | |
| CO2019008347A2 (es) | Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla | |
| UA113233U (uk) | Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента | |
| UA109243U (uk) | Тверда лікарська форма, що містить інгібітор віл протеази | |
| MX2017007166A (es) | Composicion farmaceutica de haloperidol mas quercetina con efecto analgesico en dolor neuropatico. | |
| UA113237U (uk) | Фармацевтична комбінація ацеклофенаку і снодійного або заспокійливого компонента | |
| UA98027U (uk) | Фармацевтична композиція для використання в ветеринарній медицині "коцефен 200" | |
| UA111998U (uk) | Застосування декаметоксину як фармацевтично активної речовини для лікування захворювань шлунково-кишкового тракту та кишкових інфекцій перорально |